We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
-3.65%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$342M
AUM Growth
-$111M
Cap. Flow
-$71.8M
Cap. Flow %
-21.01%
Top 10 Hldgs %
35.85%
Holding
99
New
15
Increased
34
Reduced
31
Closed
19

Top Buys

Rank Stock Value
1
THC icon
Tenet Healthcare
THC
+$8.15M
2
IRTC icon
iRhythm Holdings
IRTC
+$5.39M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$5.36M
4
LEGN icon
Legend Biotech
LEGN
+$4.76M
5
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$4.36M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$13M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$10.9M
3
AVTR icon
Avantor
AVTR
+$8.89M
4
DXCM icon
DexCom
DXCM
+$8.82M
5
DHR icon
Danaher
DHR
+$6.18M

Sector Composition

Rank Sector Weight
1 Healthcare 96.94%
2 Industrials 2.69%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRTC icon
1
iRhythm Holdings
IRTC
$4.2B
$16.4M 4.79%
103,981
+42,001
+68% +$5.39M
UTHR icon
2
United Therapeutics
UTHR
$23.1B
$13.3M 3.89%
74,107
-16,091
-18% -$3.07M
UNH icon
3
UnitedHealth
UNH
$370B
$12.9M 3.78%
25,327
-12,496
-33% -$6.03M
SGEN
4
DELISTED
Seagen Inc. Common Stock
SGEN
$12.4M 3.63%
86,096
+5,301
+7% +$717K
IMUX icon
5
Immunic
IMUX
$195M
$12.3M 3.6%
108,925
+11,507
+12% +$1.33M
THC icon
6
Tenet Healthcare
THC
$21.1B
$12M 3.5%
139,185
+99,185
+248% +$8.15M
IQV icon
7
IQVIA
IQV
$39.3B
$11.6M 3.39%
50,090
-23,022
-31% -$5.45M
ACRS icon
8
Aclaris Therapeutics
ACRS
$869M
$11.5M 3.37%
668,098
-357,424
-35% -$4.88M
DHR icon
9
Danaher
DHR
$144B
$10.8M 3.17%
41,704
-24,675
-37% -$6.18M
XENE icon
10
Xenon Pharmaceuticals
XENE
$6.12B
$9.3M 2.72%
304,186
-56,316
-16% -$1.69M
RCM
11
DELISTED
R1 RCM Inc. Common Stock
RCM
$9.18M 2.69%
342,923
+42,528
+14% +$1.04M
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$29.3B
$8.82M 2.58%
54,008
-3,674
-6% -$560K
CTLT
13
DELISTED
CATALENT, INC.
CTLT
$8.77M 2.57%
79,049
+18,110
+30% +$1.89M
CVS icon
14
CVS Health
CVS
$122B
$8.66M 2.54%
85,618
-47,716
-36% -$5.01M
CDMO
15
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$8.3M 2.43%
407,458
+117,458
+41% +$2.39M
COO icon
16
Cooper Companies
COO
$14.5B
$8.18M 2.39%
78,340
-16,520
-17% -$1.66M
BCRX icon
17
BioCryst Pharmaceuticals
BCRX
$2.4B
$7.76M 2.27%
476,978
+76,977
+19% +$1.23M
ABBV icon
18
AbbVie
ABBV
$435B
$7.41M 2.17%
45,731
-5,991
-12% -$870K
DXCM icon
19
DexCom
DXCM
$32B
$6.52M 1.91%
50,948
-80,676
-61% -$8.82M
NBIX icon
20
Neurocrine Biosciences
NBIX
$16.6B
$5.93M 1.73%
+63,234
New +$5.36M
CDXS icon
21
Codexis
CDXS
$158M
$5.53M 1.62%
268,144
-72,008
-21% -$1.49M
AVTR icon
22
Avantor
AVTR
$9.19B
$5.36M 1.57%
158,365
-249,210
-61% -$8.89M
NTRA icon
23
Natera
NTRA
$46.4B
$5.29M 1.55%
129,944
+5,394
+4% +$324K
RCUS icon
24
Arcus Biosciences
RCUS
$3.64B
$5.28M 1.55%
167,321
+50,222
+43% +$1.68M
ATEC icon
25
Alphatec Holdings
ATEC
$1.44B
$5.2M 1.52%
451,794
+216,871
+92% +$2.35M
1
2 3 4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2022 Portfolio in Review

As of Q1 2022, Parkman Healthcare Partners held 99 positions worth $342M, down 25% from $453M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Parkman Healthcare Partners withdrew a net $71.8M in Q1 2022, closing 19 positions and reducing 31 holdings. Its most notable exit was HCA Healthcare, an estimated $13M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

Against the trend, Parkman Healthcare Partners opened a new position in Neurocrine Biosciences worth $5.93M.

  • Parkman Healthcare Partners's largest Q1 2022 buy was Neurocrine Biosciences: 63,234 shares worth $5.93M.
  • Parkman Healthcare Partners added most to Tenet Healthcare in Q1 2022, an estimated $8.15M increase.
  • Parkman Healthcare Partners's biggest Q1 2022 reduction was Avantor, cutting an estimated $8.89M.
  • Parkman Healthcare Partners fully exited HCA Healthcare in Q1 2022, selling an estimated $13M.
  • Parkman Healthcare Partners's ten largest holdings make up 36% of its $342M portfolio in Q1 2022.
  • Parkman Healthcare Partners opened 15 new positions and closed 19 in Q1 2022.
  • Parkman Healthcare Partners's portfolio value fell 25% quarter-over-quarter to $342M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2022, filed 13 May 2022.